Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $33,912.00 in Stock

Posted by George Bondi on Jul 3rd, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Darin Lippoldt sold 200 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $169.56, for a total value of $33,912.00. Following the sale, the insider directly owned 54,729 shares in the company, valued at approximately $9,279,849.24. This represents a 0.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darin Lippoldt also recently made the following trade(s):

On Monday, June 29th, Darin Lippoldt sold 9,800 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $170.16, for a total value of $1,667,568.00.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $174.26 on Friday. The business has a 50 day simple moving average of $155.13 and a 200 day simple moving average of $141.58. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $174.38. The stock has a market cap of $17.52 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 0.67 and a beta of 0.39.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. increased their target price on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Canaccord Genuity Group lifted their price target on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Truist Financial boosted their price target on Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Guggenheim reiterated a “buy” rating and set a $175.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $187.52.

Get Our Latest Stock Analysis on Neurocrine Biosciences

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. USA Financial Formulas acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $25,000. Geneos Wealth Management Inc. raised its holdings in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. DJE Kapital AG bought a new stake in Neurocrine Biosciences during the fourth quarter worth about $28,000. Basecamp Wealth Advisors LLC boosted its position in Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after purchasing an additional 204 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC acquired a new position in Neurocrine Biosciences during the first quarter valued at approximately $33,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.